Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8879 | 0.67 | GPR3 (0.35) | GPR3MAPT | |
| SCHEMBL1395756 | 0.67 | MAPT (0.33) | MAPT | |
| SCHEMBL80737 | 0.62 | GPR3 (0.35) | GPR3MAPT | |
| SCHEMBL452301 | 0.62 | MAPT (0.33) | MAPT | |
| SCHEMBL5767319 | 0.60 | GPR3 (0.39) | GPR3MAPT | |
| SCHEMBL95080 | 0.60 | GPR3 (0.38) | GPR3MAPT | |
| SCHEMBL1395705 | 0.60 | — | — | |
| SCHEMBL56536 | 0.58 | MAPT (0.32) | MAPT | |
| SCHEMBL400612 | 0.58 | MAPT (0.47) | GPR3MAPT | |
| SCHEMBL23981 | 0.58 | MAPT (0.56) | GPR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946207-B2 | Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device | CANON KABUSHIKI KAISHA (JP) | 2005-09-20 | — | — | US | claimed |
| US-20020135292-A1 | Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device | CANON KABUSHIKI KAISHA (JP) | 2002-09-26 | — | — | US | claimed |
| US-5081245-A | Selective antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-01-14 | — | — | US | claimed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12497377-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-16 | — | — | US | disclosed |
| EP-3992176-B1 | EP2 ANTAGONIST | ONO PHARMACEUTICAL CO (JP) | 2025-08-27 | — | — | EP | disclosed |
| US-20250188023-A1 | BENZENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-12 | — | — | US | disclosed |
| US-12258308-B2 | Benzene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-25 | — | — | US | disclosed |
| US-20250042870-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| US-20250034187-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-30 | — | — | US | disclosed |
| US-20020135292-A1 | Electroconductive device, organic electroluminescence device using the device and process for producing the electroconductive device | CANON KABUSHIKI KAISHA (JP) | 2002-09-26 | — | — | US | disclosed |
| US-20010053377-A1 | Process for increasing the persistence of at least one cosmetic effet and/or care effect of a cosmetic composition, cosmetic composition and use thereof | L'OREAL (FR) | 2001-12-20 | — | — | US | disclosed |
| US-20010051171-A1 | Cosmetic use of at least one polyorganosiloxane as a gelling agent and cosmetic composition containing it | L'OREAL (FR) | 2001-12-13 | — | — | US | disclosed |
| US-6051722-A | PRECURSOR FOR POLYIMIDE COPOLYMER; USABLE IN OPTICAL LONG-DISTANCE COMMUNICATION, SIGNAL PROCESSING, PHOTOELECTRIC HYBRID CIRCUITS AND OPTICAL COMPUTERS | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2000-04-18 | — | — | US | disclosed |
| US-5834575-A | POLYIMIDE OR POLYACRYLATE WITH PENDANT GROUP CONTAINING THIOPHENE RING, BENZENE RING AND VICINAL NITRILE GROUPS, SWITCHES FOR OPTICAL SIGNALS, COMMUNICATION TECHNOLOGY | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5081245-A | Selective antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| US-4952490-A | LOW FOG; HIGH SPEED DEVELOPMENT | FUJI PHOTO FILM CO., LTD. (JP) | 1990-08-28 | — | — | US | disclosed |
| US-4952491-A | LOW FOG AND HIGH SPECTRAL SENSITIVITY; RAPID PROCESSING; CRYSTAL HABIT CONTROL | FUJI PHOTO FILM CO., LTD. (JP) | 1990-08-28 | — | — | US | disclosed |
| EP-0356765-A2 | Carboxylic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034187-A1 | STING AGONISTIC COMPOUND | STING1, IRF3, MAVS | GPR3 320/4885MAPT 4099/4885 |
| US-12258308-B2 | Benzene derivative | PMP22, TMBIM6, MYT1 | GPR3 4558/4885MAPT 2169/4885 |
| US-20250188023-A1 | BENZENE DERIVATIVE | PMP22, TMBIM6, MYT1 | GPR3 4563/4885MAPT 2085/4885 |
| US-20010053377-A1 | Process for increasing the persistence of at least one cosmetic effet and/or care effect of a cosmetic composition, cosmetic composition and use thereof | CUTA, LAGE3, MITF | GPR3 1493/4885MAPT 602/4885 |
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | GPR3 71/4885MAPT 4697/4885 |
| US-12497377-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | GPR3 113/4885MAPT 4700/4885 |
| US-20250042870-A1 | DP ANTAGONIST | OPRL1, CNR1, NPSR1 | GPR3 37/4885MAPT 3282/4885 |
| US-20010051171-A1 | Cosmetic use of at least one polyorganosiloxane as a gelling agent and cosmetic composition containing it | CUTA, LPO, PRDX1 | GPR3 3868/4885MAPT 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.